About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, an oral agent for the treatment of diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-965.03%
Return on Assets-151.95%
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Frequently Asked Questions
What is Ampio Pharmaceuticals' stock symbol?
Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."
How were Ampio Pharmaceuticals' earnings last quarter?
Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) announced its quarterly earnings data on Tuesday, February, 24th. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.01. The specialty pharmaceutical company earned $0.02 million during the quarter. View Ampio Pharmaceuticals' Earnings History.
Are investors shorting Ampio Pharmaceuticals?
Ampio Pharmaceuticals saw a decrease in short interest in May. As of May 31st, there was short interest totalling 10,472,904 shares, a decrease of 6.6% from the May 15th total of 11,209,042 shares. Based on an average trading volume of 806,646 shares, the short-interest ratio is currently 13.0 days. Approximately 13.5% of the shares of the company are sold short.
Who are some of Ampio Pharmaceuticals' key competitors?
Some companies that are related to Ampio Pharmaceuticals include Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD) and IMV (IMV).
Who are Ampio Pharmaceuticals' key executives?
Ampio Pharmaceuticals' management team includes the folowing people:
- Mr. Michael Macaluso, Founder, Chairman & CEO (Age 66)
- Mr. Thomas E. Chilcott III, CFO & Sec. (Age 50)
- Ms. Holli Cherevka, Chief Operating Officer (Age 35)
- Dr. David Bar-Or M.D., Chief Scientific Officer & Director (Age 69)
- Mr. Philip H. Coelho, Director (Age 74)
Has Ampio Pharmaceuticals been receiving favorable news coverage?
Media coverage about AMPE stock has trended somewhat positive on Monday, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ampio Pharmaceuticals earned a daily sentiment score of 0.05 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 47.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Ampio Pharmaceuticals' major shareholders?
Ampio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.91%), Tibra Equities Europe Ltd (0.20%), Cypress Capital Management LLC WY (0.20%), Prosight Management LP (0.13%), Noven Financial Group Inc. (0.12%) and Brighton Jones LLC (0.10%). View Institutional Ownership Trends for Ampio Pharmaceuticals.
Which institutional investors are selling Ampio Pharmaceuticals stock?
Which institutional investors are buying Ampio Pharmaceuticals stock?
AMPE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tibra Equities Europe Ltd, Prosight Management LP, Element Capital Management LLC, A.R.T. Advisors LLC, Cypress Capital Management LLC WY and Brighton Jones LLC. View Insider Buying and Selling for Ampio Pharmaceuticals.
How do I buy shares of Ampio Pharmaceuticals?
Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ampio Pharmaceuticals' stock price today?
One share of AMPE stock can currently be purchased for approximately $1.82.
How big of a company is Ampio Pharmaceuticals?
Ampio Pharmaceuticals has a market capitalization of $197.70 million.
How can I contact Ampio Pharmaceuticals?
Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The specialty pharmaceutical company can be reached via phone at +1-720-4376500.
MarketBeat Community Rating for Ampio Pharmaceuticals (AMPE)MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPE will underperform the S&P 500 over the long term. You may vote once every thirty days.